End to End Brexit Support Services for Life Sciences

Brexit Support.
Regulatory Done Right.

Since Brexit, life sciences companies operating across UK and European markets must navigate two entirely separate and increasingly divergent regulatory frameworks — MHRA and EMA. Two submissions. Two compliance programmes. Two sets of ongoing obligations.And with the EU Pharma Package now accelerating regulatory divergence between UK and EU, the complexity is only growing. Many companies don't know where they stand — or what they need to do next. At BioReg Life Sciences we cut through that complexity. We provide clear regulatory guidance on your post Brexit position, honest gap analysis of exactly where you stand against dual market requirements and complete end to end eCTD publishing and submission management for both MHRA and EMA.We are UK based with deep MHRA expertise — and a proven track record of successful EMA submissions across thousands of projects. Whatever your Brexit regulatory challenge, we give you clarity, direction and the submission capability to act on it. Regulatory Affairs. Done Right.

Discussing Brexit and life sciences challenges_edited_edited.jpg

Brexit Gap Analysis

Before you can address your post Brexit regulatory position you need to understand exactly where you stand. Many life sciences companies are operating with a regulatory compliance gap they are not fully aware of — either because they have not yet established a UK regulatory programme, because their EU programme has not kept pace with post Brexit requirements or because the divergence between MHRA and EMA frameworks has created new gaps in their existing compliance position.

At BioReg Life Sciences our Brexit gap analysis gives you a comprehensive and honest assessment of your current regulatory position against the specific requirements of both MHRA and EMA post Brexit. We identify exactly what you have, what you are missing and what you need to do to achieve full dual market compliance — delivering a clear prioritised roadmap that tells you precisely where to focus your regulatory effort and investment.

Whether you are a UK company that has not yet addressed EU market access or a European company that has not yet established a compliant UK regulatory programme — our Brexit gap analysis gives you the clarity and direction to act decisively and efficiently.

Brexit Regulatory Guidance

Brexit has created a fundamentally new regulatory landscape for life sciences companies operating across UK and European markets — and navigating it without expert guidance is one of the most common and costly mistakes companies make. Understanding what has changed, what it means for your specific product and what you need to do next requires clear, experienced and honest regulatory advice.

At BioReg Life Sciences we provide straightforward Brexit regulatory guidance — helping pharmaceutical, biotech, gene therapy and medical device companies understand exactly what the post Brexit regulatory environment means for them. We advise on the differences between MHRA and EMA requirements, the implications of the EU Pharma Package for your regulatory programme, the most efficient dual market strategy for your specific product and the key regulatory decisions you need to make now to protect your market access going forward.

Our guidance is practical, specific and actionable — not generic advice but honest expert direction tailored to your product, your markets and your regulatory position. We tell you exactly what you need to know and exactly what you need to do next.

Regulatory Submissions and eCTD Publishing

Submitting a regulatory application to the MHRA, EMA or FDA is the culmination of years of development and investment. It must be right. There is no margin for error.

At BioReg Life Sciences, we manage the end-to-end submission process — from initial planning through to submission confirmation and authority query management. Our team has completed over 5,000 submissions across global markets with a 100% acceptance rate. We know what works, what regulators expect and how to avoid the common pitfalls that delay approvals.

eCTD publishing is the technical backbone of every modern submission. Using industry leading Freyr software, we compile, hyperlink, validate and quality check your complete eCTD dossier to ensure full technical compliance with MHRA, EMA, FDA and all major global health authorities. Every document, every hyperlink, every bookmark and every piece of metadata is checked before your submission ever leaves our hands.

We act as your single point of contact throughout — coordinating all workstreams, managing authority queries and ensuring nothing falls through the cracks. Whether this is your first submission or your fiftieth, BioReg Life Sciences brings the senior expertise, technical precision and project management rigour to get your application approved.

Lifecycle Management

Regulatory approval is not the finish line — it is the beginning of an ongoing compliance commitment. Post approval, your product must remain continuously compliant through variations, renewals, labelling updates, safety reporting and regular interactions with regulatory authorities. For many companies this is where the cracks start to appear.

At BioReg Life Sciences we manage your complete regulatory lifecycle so they never do. From post approval variations and PSUR submissions to authority query management and product renewals, we handle every obligation with the same precision we bring to initial submissions. Your full regulatory dossier is securely hosted in our managed document system, giving you continuous access to your submission history and compliance records at all times.

With BioReg Life Sciences managing your lifecycle, your product stays compliant, your team stays focused and your business keeps moving forward.

Lifecycle Management

With BioReg Life Sciences managing your lifecycle, your product stays compliant, your team stays focused and your business keeps moving forward.

Professional office consultation in action.png

UK Marketing Authorisation Support

For European companies seeking UK market access post Brexit, obtaining a UK Marketing Authorisation from the MHRA is no longer a straightforward extension of your EU approval. The MHRA now operates its own fully independent regulatory framework — with its own specific dossier requirements, its own technical standards and its own submission processes that differ from the EMA pathway in important ways.

At BioReg Life Sciences we provide expert regulatory guidance and complete eCTD submission management for European companies pursuing UK Marketing Authorisation. We advise on the UK specific regulatory requirements for your product, guide you through the MHRA submission process and manage your complete UK eCTD submission — from initial regulatory assessment and gap analysis through to dossier compilation, publishing, validation and electronic submission to the MHRA.

We know the MHRA inside out. We understand what they expect, how they work and what a successful UK submission looks like. You focus on your European operations — we open the UK market for you efficiently, compliantly and with complete confidence in the outcome.

Legacy Dossier Splitting

Many life sciences companies operating before Brexit had a single integrated regulatory dossier covering both UK and EU market access simultaneously. Post Brexit that dossier now needs to exist as two separate independently maintained versions — each structured, formatted and technically compliant with the specific eCTD requirements of their respective regulatory authority.

At BioReg Life Sciences we manage the complete legacy dossier splitting process — reviewing your existing dossier in detail, identifying all UK and EU specific differences and producing two fully compliant standalone eCTD dossiers ready for independent lifecycle management in both markets. We handle the complete technical splitting process — restructuring, reformatting, revalidating and resubmitting your dossier as two separate compliant submissions to MHRA and EMA respectively.

Both dossiers are securely hosted in our managed document system following splitting — giving you continuous access to your complete UK and EU regulatory history and complete confidence in your dual market regulatory position going forward. One process managed end to end by BioReg Life Sciences.

Dual MHRA & EMA Submissions

Managing simultaneous submissions to both MHRA and EMA post Brexit is one of the most technically demanding regulatory challenges a life sciences company can face. Two separate dossiers. Two separate technical requirements. Two separate eCTD structures. Two separate electronic submission gateways. Two separate authority interactions and timelines — all requiring the same level of precision and compliance.

At BioReg Life Sciences we manage the complete dual submission process — compiling, publishing, validating and submitting your regulatory dossiers to both MHRA and EMA simultaneously. Using industry leading Freyr software we ensure every submission is technically compliant with the specific requirements of each authority — formatted correctly, validated thoroughly and submitted through the correct gateway accurately and on time.

With over 5,000 submissions completed and a 100% acceptance rate across MHRA, EMA and global markets — dual submission management is exactly what we do. One partner managing both submissions simultaneously — with complete accountability for the outcome in both markets.

Dual Lifecycle Management

Post approval compliance across two separate regulatory frameworks simultaneously is one of the most significant and ongoing challenges created by Brexit. Every variation, every renewal and every post approval submission now needs to be managed separately for UK and EU — with different eCTD technical requirements, different timelines and different regulatory authority interactions for each market.

At BioReg Life Sciences we provide complete dual lifecycle management — handling your post approval eCTD submissions in both markets simultaneously through a single trusted partner. We manage your UK and EU variations, renewals and post approval sequences — compiling, publishing, validating and submitting every lifecycle update to the correct authority accurately and on time.

Your complete UK and EU dossiers are securely hosted in our managed Freyr document system — giving you continuous access to your full regulatory history across both markets at all times. With BioReg Life Sciences managing your dual lifecycle programme you can be confident that every post approval obligation in both markets is being handled to the same uncompromising standard — nothing missed, nothing delayed, nothing left to chance.

UKCA & CE Marking Guidance

For medical device manufacturers selling in both UK and European markets, understanding the differences between UKCA and CE marking requirements and developing an efficient strategy for achieving and maintaining both simultaneously has become one of the most pressing post Brexit regulatory priorities. The two frameworks are diverging — creating increasing complexity and cost for manufacturers operating across both markets.

At BioReg Life Sciences we provide clear and practical UKCA and CE marking regulatory guidance — helping medical device manufacturers understand exactly what each framework requires, how they differ and the most efficient strategic approach to achieving and maintaining dual market compliance for their specific device and classification.

We advise on conformity assessment routes, approved and notified body engagement strategy, technical documentation requirements and the key regulatory decisions that determine how efficiently and cost effectively you can achieve compliance in both markets. Our guidance gives you the clarity to make the right strategic decisions early — before they become costly ones to reverse — and the roadmap to execute your dual market device regulatory programme with confidence.

Why choose BioReg Life Sciences for your regulatory needs?

BioReg Life Sciences supports pharmaceutical, biotech and gene therapy companies with every stage of the regulatory journey — from early development through to post-authorisation and lifecycle management. Whatever your regulatory challenge, our senior consultants work with you to build a balanced, realistic and achievable strategy that aligns with your company's vision. We manage and publish your submissions, advise on complex regulatory requirements, and support your successful market launch and ongoing compliance.Talk to us for an open, no-obligation conversation about how we can help.

Brexit Support. Regulatory Done Right.

Brexit Gap Analysis

​

Why choose BioReg Life Sciences for your regulatory needs?

Brexit Support.
Regulatory Done Right.